NCT02976467 - A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction | Biotech Hunter

Enrollment

107

Participants

Timeline

Start Date

December 30, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

September 4, 2018

Conditions

Myocardial Infarction

Interventions

DRUG

Fulacimstat (BAY1142524)

25 mg BAY 1142524 are given twice daily over a treatment period of 6 months

DRUG

Placebo

Matching placebo tablets are given twice daily over a treatment period of 6 months

Trial Locations (25)

13353

Berlin

20089

Milan

20090

Monza-Brianza

20138

Milan

24127

Bergamo

25123

Brescia

27259

Kladno

28007

Madrid

28040

Madrid

30625

Hanover

36312

Babio - Beade

44137

Dortmund

46026

Valencia

99089

Erfurt

3109601

Haifa

4941492

Petah Tikva

6423906

Tel Aviv

8410101

Beersheba

9103102

Jerusalem

9112001

Jerusalem

100 34

Prague

140 21

Prague

150 06

Prague

150 30

Prague

08036

Barcelona